January 4, 2010
"ASKLEP 2nd ANNUAL GLOBAL CONFERENCE" - February 17th 2010
ASKLEP Inc., a Japan based CRO providing clinical research services, is pleased to announce "ASKLEP 2nd ANNUAL GLOBAL CONFERENCE" to be held on February 17th, 2010 at the Tokyo International Forum.
The globalization of clinical development has been advancing rapidly and Asia, on a regional basis, is no exception. ASKLEP recognized this early and began establishing a network of CROs in Asia. The focus for this conference is to provide insight and the latest in regulatory changes in strategic markets for clinical development, Taiwan and Korea. There will also be other topics covered and is geared toward Research and Development professionals at biotech, pharmaceutical and device manufacturers.
The conference will feature speakers from ASKLEP's regional CRO Asia network, and we will also have guest speakers from Pharmaceutical industry participating.
Conference Information (http://www.asklep.co.jp/conference/)
Date: February 17th, 2010
Time: 14:00 - 18:00 (18:15- Reception)
Place: Tokyo International Forum (Yurakucho) B-Block 5th Floor
http://www.t-i-forum.co.jp/english/index.html
About ASKLEP
Asklep, Inc., (http://www.asklep.co.jp) founded in 1992, in Tokyo, Japan, provides clinical research services in monitoring, data management, biostatistics, regulatory & consulting, CRA training, etc. ASKLEP is an INTAGE Group Company. INTAGE, INC., (http://www.intage.co.jp) is the largest marketing research company in Japan and the eleventh largest globally. It has one of the most comprehensive healthcare solution services in the industry
About Qualitix Clinical Research
Qualitix Clinical Research Co., Ltd. (http://www.qualitix.com.tw/) Qualitix is a full service CRO based in Taiwan and focuses on clinical monitoring and site management services for multinational phase II and phase III studies. Qualitix was established in June 2008; however, CRO business was commenced since 1997 under its parent company Genovate Biotechnology Co., Ltd. This year, Qualitix has established its presence in China and expanding its service area to China.
About Dream CIS
With abundant experience and know-how, DreamCIS (http://www.dreamcis.com) helps pharmaceutical, biotech and device manufacturers plan and manage trials from beginning to end. DreamCIS strengths are study consulting and study design, medical writing and feasibility for patient recruitment along with subsequent clinical monitoring. DreamCIS provides clinical trial services, either for an entire project or certain stages of a project, that meet client needs, in accordance with KGCP, GCP and ICH guidelines. Since the company established in 2000, DreamCIS has conducted 255 clinical trials in Phase I to IV, and over 480 projects in Pharmacovigilance and Post-Marketing Surveillance.
Contact: ASKLEP Corporate Planning and Development Dept. Tel: 81-3-5294-5223
